Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24047858 | 0.96 | CASP2 (0.74) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL24415976 | 0.87 | CASP2 (0.60) | CASP2NAAAFAAHALDH1A1DNM1 | |
| SCHEMBL25920826 | 0.86 | CASP2 (0.92) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL13019127 | 0.86 | CASP2 (0.92) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL14199967 | 0.86 | CASP2 (0.91) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23337627 | 0.85 | CASP2 (0.69) | CASP2NAAAEPHX1FAAHDNM1 | |
| SCHEMBL7537764 | 0.84 | CASP2 (0.86) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL12738558 | 0.82 | CASP2 (1.00) | CASP2NAAAEPHX1FAAHDNM1 | |
| SCHEMBL5065624 | 0.82 | CASP2 (1.00) | CASP2NAAAEPHX1FAAHDNM1 | |
| SCHEMBL10149806 | 0.82 | CASP2 (1.00) | CASP2NAAAEPHX1FAAHDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220145292-A1 | LIGAND CLUSTERS AND METHODS OF THEIR USE AND PREPARATION | DEEP GENOMICS INCORPORATED (CA) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220145292-A1 | LIGAND CLUSTERS AND METHODS OF THEIR USE AND PREPARATION | ST6GAL1, FUT5, CXCR2 | CASP2 3291/4885NAAA 3775/4885EPHX1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.